hervcov
“Understand the pathogenic role of HERV-W envelope protein and develop novel prognostic markers and therapeutic targets for personalized treatment of COVID-19-associated syndromes”
These are the goals of a project involving researchers from 5 different EU countries. This study has already produced evidence for the induction of a specific protein during COVID-19 disease. New information to guide predictive and personalized medicine may be obtained in the near future thanks to this discovery.
September 10 and 11 2025, Annual Meeting in Athens
HERVCOV: new insights into the role of human endogenous retroviruses in Long COVID
The European project HERVCOV announces significant progress in the study of Long COVID disease, which frequently follows COVID-19 infection, offering new evidence on the role of human endogenous retroviruses (HERVs) — in particular, the HERV-W envelope (ENV) protein — in the persistence of symptoms following SARS-CoV-2 infection.
On September 10–11, 2025, researchers from the HERVCOV consortium will meet in Athens for the Third Annual Meeting, which will include an outreach event open to the general public to share the project’s latest findings.
THE 2025 CONSORTIUM MEETING
This year, Greece will host the consortium’s annual gathering. The event will be held at the National and Kapodistrian University of Athens, featuring two full days of presentations, discussions, and networking among project partners.
September 10 will be dedicated to internal meetings, during which partners will present the scientific progress achieved over the past year.
September 11 will focus on public engagement, offering an opportunity to present results to non-specialist audiences and raise awareness about Long COVID and ongoing research efforts.
HERVCOV Project
It is called HERVCOV project, and it has received funding from the European Commission with almost 7 million euros, involving organizations and companies from Italy, Croatia, France, Greece and Spain. The research consortium has been collaborating since almost one year in the study of the protein, which derives from the ENV sequence of human endogenous retrovirus W (HERV-W ENV).
Human endogenous retroviruses (HERVs) currently make up 8% of the human genome. The activation of some HERV sequences has been associated with various physiological and pathological conditions. Consortium research groups have shown that activation of the HERV-W-ENV protein by SARS-CoV-2 is associated with severe forms of COVID-19. On May 5, the World Health Organization ruled the end of the health emergency caused by the COVID-19 pandemic. However, there are still many inflammatory, cognitive and neurological consequences due to SARS-CoV-2 infection, known as Post COVID-19 syndromes.
What is Post COVID-19
The World Health Organization defines “Post COVID-19” as a series of medium- and long-term effects after the initial illness. Symptoms can be different between different people, adults or children. Overall, the most common symptoms of the Post COVID-19 condition include: fatigue, difficulty breathing, memory, concentration or sleep problems, persistent cough, chest pain, difficulty speaking, body aches, sense of smell or taste loss, depression or anxiety.
These symptoms could be associated with persistent inflammation also due to the possibility, not yet clarified, that the SARS-CoV-2 infection may remain in reservoirs located in different parts of the body even for a long time compared to the primary infection.
Research progression
The study on which the HERVCOV project is based demonstrated in COVID-19 patients the high expression of the HERV-W-ENV protein not only at the blood level, but also at the entry site of SARS-CoV-2, i.e. in the nasopharyngeal tract. In fact, HERV-W has already been detected in molecular swabs. Furthermore, HERV-W ENV is persistently expressed even several weeks/months/years after infection in people with Post COVID-19 syndrome. In healthy individuals who have never encountered SARS-CoV-2 and in those who have contracted the virus but have completely recovered, however, the protein is not expressed.
June 8 and 9, Annual Meeting in Rome
On June 8 and 9 there was the first Annual Meeting of the project, during which the researchers of the partnership gathered for conference activities at the Rectorate of the University of Rome “Tor Vergata”.
On June 9 there was also an afternoon dedicated to dissemination hosted in Frascati. Here it has been possible, in addition to visiting the places in the HERVCOV Metaverse, to meet associations involved in scientific dissemination, wear the lab coat and extract the DNA from the fruit, or reproduce the double helix model and discover the differences with the RNA. Researchers of the HERVCOV project were available to answer all questions, furthermore they presented laboratories and quizzes to show the functioning of human endogenous retroviruses.
THE PARTNERS
HERVCOV, “SARS-CoV-2-induced activation of pathogenic endogenous retrovirus envelope HERV-W: towards personalized treatment of COVID-19 patients” is funded under the HORIZON-HLTH-2021-DISEASE call (Personalised medicine and infectious disease: understanding the individual host response to viruses) of the European Commission under the Horizon Europe Framework Programme and it will involve the following partners: Institut National de la Santé et de la Recherche Médicale (France), Ethniko Kai Kapodistriako Panepistimio Athinon (Greece), Rome Tor Vergata University (Italy), Instituto Aragonés de Ciencias de la Salud (Spain), Fundación Agencia Aragonesa para la Investigación y el Desarrollo (Spain), Geneuro Innovation SAS (France), Inserm Transfert (France), Klinicki Bolnicki Centar Rijeka (Croatia) and Frascati Scienza (Italy).
This project has received funding from the European Union’s Horizon Europe research and innovation program under grant agreement No 101057302.
Consortium Meeting 2024 - Zaragoza
